AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.130
0.00 (0.00%)
At close: Jan 30, 2026, 4:00 PM EST
1.120
-0.010 (-0.88%)
After-hours: Jan 30, 2026, 7:09 PM EST
AN2 Therapeutics Employees
AN2 Therapeutics had 22 employees as of December 31, 2024. The number of employees decreased by 19 or -46.34% compared to the previous year.
Employees
22
Change (1Y)
-19
Growth (1Y)
-46.34%
Revenue / Employee
n/a
Profits / Employee
-$1,544,818
Market Cap
30.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 22 | -19 | -46.34% | 22 | 0 |
| Dec 31, 2023 | 41 | 5 | 13.89% | 41 | 0 |
| Mar 31, 2023 | 36 | 14 | 63.64% | 35 | 1 |
| Dec 31, 2022 | 36 | 14 | 63.64% | 35 | 1 |
| Sep 30, 2022 | 27 | 5 | 22.73% | 26 | 1 |
| Jun 30, 2022 | 25 | - | - | 25 | 0 |
| Mar 31, 2022 | 22 | - | - | 22 | 0 |
| Dec 31, 2021 | 22 | - | - | 22 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Kyntra Bio | 225 |
| Barinthus Biotherapeutics | 105 |
| Cue Biopharma | 41 |
| Werewolf Therapeutics | 39 |
| NeuroSense Therapeutics | 17 |
| Outlook Therapeutics | 17 |
| Skye Bioscience | 16 |
| Hyperion DeFi | 14 |
ANTX News
- 19 days ago - AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease - Business Wire
- 2 months ago - AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 2 months ago - AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) - Business Wire
- 3 months ago - AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference - Business Wire
- 6 months ago - AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 6 months ago - AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease - Business Wire
- 6 months ago - AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease - Business Wire
- 7 months ago - AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole - Business Wire